Raphael Pharmaceutical Stock Price To Earning
RAPH Stock | 0.26 0.00 0.00% |
Raphael Pharmaceutical fundamentals help investors to digest information that contributes to Raphael Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Raphael OTC Stock. The fundamental analysis module provides a way to measure Raphael Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Raphael Pharmaceutical otc stock.
Raphael |
Raphael Pharmaceutical OTC Stock Price To Earning Analysis
Raphael Pharmaceutical's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition |
Based on the latest financial disclosure, Raphael Pharmaceutical has a Price To Earning of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Price To Earning (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Raphael Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Raphael Pharmaceutical's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Raphael Pharmaceutical could also be used in its relative valuation, which is a method of valuing Raphael Pharmaceutical by comparing valuation metrics of similar companies.Raphael Pharmaceutical is currently under evaluation in price to earning category among its peers.
Raphael Fundamentals
Return On Asset | -19.04 | |||
Shares Outstanding | 15.62 M | |||
EBITDA | (1.63 B) | |||
Net Income | (1.62 B) | |||
Book Value Per Share | (0) X | |||
Cash Flow From Operations | (1.42 M) | |||
Market Capitalization | 17.19 M | |||
Total Asset | 422 K | |||
Net Asset | 422 K |
About Raphael Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Raphael Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Raphael Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Raphael Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Raphael OTC Stock
Raphael Pharmaceutical financial ratios help investors to determine whether Raphael OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Raphael with respect to the benefits of owning Raphael Pharmaceutical security.